0|10000|Public
50|$|Because of {{the species}} limited distribution, the {{clearance}} of the forest, and the pollution and consumption of the water byhumans, it is classified by the IUCN as a critically endangered species (Shaffer <b>et</b> <b>al.</b> 2004) and as a threatened species by the Mexican government (SEMARNAT 2010). In the geographic distribution {{of the species}}, there are several threats that are modifying the ecosystem, including alteration of the stream to collect the water for human consumption, introduction of cattle, and the direct collection of specimens for traditional food (Sunny <b>et</b> <b>al.</b> <b>2014b).</b>|$|R
25|$|Most recently, Bertness {{and colleagues}} (Bertness <b>et</b> <b>al.</b> <b>2014b)</b> {{performed}} a field experiment excluding predators from plots on the grazing {{border of the}} marsh. Within one growing season, exclusion of top predators triggered die-off by increasing the abundances of Sesarma crabs {{and the intensity of}} herbivory. To further test the trophic cascade hypothesis, Bertness and colleagues used the spread of die-off into Narragansett Bay to assess all proposed drivers of die-off, including: 1) eutrophication decreases plant investment into belowground biomass causing plant collapse, 2) boat wakes erode creek banks, 3) pollution or disease affect plant health, 4) substrate hardness controls herbivorous crab distributions and 5) trophic dysfunction releases Sesarma from predator control. Nitrogen availability, wave intensity and plant growth did not explain any variation in die-off. However, herbivory explained over 70% of inter-site variation in die-off. (Bertness <b>et</b> <b>al.</b> 2014a) This work highlighted one particular example where top-down interactions were experimentally shown to be the primary driver of ecological community state change.|$|R
30|$|To test how drought {{influences}} both carbon isotope {{discrimination and}} stem growth, {{we used the}} BILJOU water balance model (Granier <b>et</b> <b>al.</b> 1999) to characterize annual soil water availability at each site between 1997 and 2010. Using {{the output of the}} model we then identified drought and non-drought years for each FunDivEUROPE site, as is described in detail in Grossiord <b>et</b> <b>al.</b> (<b>2014,b).</b> Briefly, the BILJOU model uses daily meteorological data (precipitation, global radiation, air temperature and humidity, wind speed), alongside information on soil water holding capacity and leaf area index to predict temporal variation in soil water content. Daily meteorological data were obtained from the CGMS database of interpolated meteorological data (AGRI 4 CAST, [URL] while soil water holding capacity and leaf area index were assessed in situ. Specifically soil water holding capacity was estimated on the basis of soil depth and type, while leaf area index was quantified using an LAI- 2000 analyser (LI-COR).|$|R
50|$|Most recently, Bertness {{and colleagues}} (Bertness <b>et</b> <b>al.</b> <b>2014b)</b> {{performed}} a field experiment excluding predators from plots on the grazing {{border of the}} marsh. Within one growing season, exclusion of top predators triggered die-off by increasing the abundances of Sesarma crabs {{and the intensity of}} herbivory. To further test the trophic cascade hypothesis, Bertness and colleagues used the spread of die-off into Narragansett Bay to assess all proposed drivers of die-off, including: 1) eutrophication decreases plant investment into belowground biomass causing plant collapse, 2) boat wakes erode creek banks, 3) pollution or disease affect plant health, 4) substrate hardness controls herbivorous crab distributions and 5) trophic dysfunction releases Sesarma from predator control. Nitrogen availability, wave intensity and plant growth did not explain any variation in die-off. However, herbivory explained over 70% of inter-site variation in die-off. (Bertness <b>et</b> <b>al.</b> 2014a) This work highlighted one particular example where top-down interactions were experimentally shown to be the primary driver of ecological community state change.|$|R
5000|$|Spatially {{resolved}} Star formation History (SFH): {{the spectra}} of galaxies encode their history of star formation: how many stars, of what mass and metal content, formed {{at which time}} along {{the evolution of the}} galaxy. Stars of different mass evolve at very different rates: while stars of 1 solar mass live for ten billion years (10 Gyr), those of 10 times the solar mass live only 32 million years (32 Myr). These wildly different rates of evolution are encoded in the spectra of galaxies, so we can use our knowledge of stellar evolution to unfold how galaxies formed their stars along time in a sort of galactic archeology. For this purpose we use several numerical codes, such as STARLIGHT; and because with CALIFA we can make these studies in 3D -for each of the two spatial coordinates we have the time evolution-, we have developed the PyCASSO analysis pipeline (Cid Fernandes <b>et</b> <b>al.,</b> 2013, 2014). We have found that: stellar mass assembly in typical massive galaxies happens from inside-out (Pérez <b>et</b> <b>al.,</b> 2013). We also found that the SFH of bulges and early-type galaxies are fundamentally related to the total stellar mass, while for disk galaxies it is more related to the local stellar mass density, and how these manifest in the mass-metallicity relation for stars and for the gas (González Delgado <b>et</b> <b>al.,</b> 2014a, <b>2014b).</b>|$|R
30|$|Several {{major issues}} {{were found for}} both knee-to-knee and knee-to-ankle mosaicplasty procedure. The type of study was poorly scored and {{included}} small sample sizes (n[*]<[*] 20) (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Gautier <b>et</b> <b>al.</b> 2002; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009). In addition, the procedure for assessing the outcomes (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014) and {{the description of the}} subject selection process (Hangody <b>et</b> <b>al.</b> 2010; Espregueira-Mendes <b>et</b> <b>al.</b> 2012; Reddy <b>et</b> <b>al.</b> 2007; Ahmad & Jones 2015; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009; Kreuz <b>et</b> <b>al.</b> 2006) were also poorly reported across the included original studies.|$|R
30|$|Other {{themes were}} less well-represented by checklists: 13 checklists (52 %) {{contained}} no items on “Team working”(Lee <b>et</b> <b>al.</b> 2009; Lobo <b>et</b> <b>al.</b> 2005; Millington <b>et</b> <b>al.</b> 2009; Murphy <b>et</b> <b>al.</b> 2008; Rosen <b>et</b> <b>al.</b> 2009; Ramakrishna <b>et</b> <b>al.</b> 2005; Blaivas and Adhikari 2009; Carvalho 2007; Stone <b>et</b> <b>al.</b> 2010; Kilbourne <b>et</b> <b>al.</b> 2009; Coopersmith <b>et</b> <b>al.</b> 2002; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); 14 checklists (56 %) contained no items on “Communication {{and working with}} the patient” (Berenholtz <b>et</b> <b>al.</b> 2004; Blaivas and Adhikari 2009; Britt <b>et</b> <b>al.</b> 2009; Carvalho 2007; Coopersmith <b>et</b> <b>al.</b> 2002; Kilbourne <b>et</b> <b>al.</b> 2009; Lobo <b>et</b> <b>al.</b> 2005; McKee <b>et</b> <b>al.</b> 2008; Millington <b>et</b> <b>al.</b> 2009; Papadimos <b>et</b> <b>al.</b> 2008; Stone <b>et</b> <b>al.</b> 2010; Velmahos <b>et</b> <b>al.</b> 2004; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); seven checklists (28 %) contained no items on “Post-procedure” (Ramakrishna <b>et</b> <b>al.</b> 2005; Blaivas and Adhikari 2009; Carvalho 2007; Stone <b>et</b> <b>al.</b> 2010; Kilbourne <b>et</b> <b>al.</b> 2009; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); seven checklists (28 %) contained no items on “Safety” (Berenholtz <b>et</b> <b>al.</b> 2004; McKee <b>et</b> <b>al.</b> 2008; Millington <b>et</b> <b>al.</b> 2009; Papadimos <b>et</b> <b>al.</b> 2008; Ramakrishna <b>et</b> <b>al.</b> 2005; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); and six checklists (24 %) contained no items on “Procedural competence” (Coopersmith <b>et</b> <b>al.</b> 2002; Costello <b>et</b> <b>al.</b> 2008; Lobo <b>et</b> <b>al.</b> 2005; McKee <b>et</b> <b>al.</b> 2008; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007).|$|R
30|$|One {{hundred and}} twenty-eight {{articles}} described 350 cases of NOVC bacteraemia involving 347 patients, 3 of whom {{presented with a}} second episode (Additional file 1 : Table S 1) (Petsaris <b>et</b> <b>al.</b> 2010; Mannion and Mellor 1986; Lai <b>et</b> <b>al.</b> 2012; Morris <b>et</b> <b>al.</b> 1981; Anderson <b>et</b> <b>al.</b> 2004; Pierce <b>et</b> <b>al.</b> 2000; Hlady and Klontz 1996; Magnusson and Pegg 1996; Robins-Browne <b>et</b> <b>al.</b> 1977; Eltahawy <b>et</b> <b>al.</b> 2004; Marcenac <b>et</b> <b>al.</b> 1991; Ferreira <b>et</b> <b>al.</b> 2012; Zarate <b>et</b> <b>al.</b> 2011; Goei and Karthigasu 1978; Trubiano <b>et</b> <b>al.</b> 2014; Heath <b>et</b> <b>al.</b> 2001; Guard <b>et</b> <b>al.</b> 1980; Hsu <b>et</b> <b>al.</b> 2013; Huhulescu <b>et</b> <b>al.</b> 2007; Halabi <b>et</b> <b>al.</b> 1997; Berghmans <b>et</b> <b>al.</b> 2002; Kadkhoda <b>et</b> <b>al.</b> 2012; Burns <b>et</b> <b>al.</b> 1989; Ramsingh 1998; Briceno <b>et</b> <b>al.</b> 2009; Young <b>et</b> <b>al.</b> 1991; Lu <b>et</b> <b>al.</b> 2014; Farmachidi <b>et</b> <b>al.</b> 2003; Chong <b>et</b> <b>al.</b> 1985; Choi <b>et</b> <b>al.</b> 2003; Dalsgaard <b>et</b> <b>al.</b> 2000; Marek <b>et</b> <b>al.</b> 2013; Aguinaga <b>et</b> <b>al.</b> 2009; Forné <b>et</b> <b>al.</b> 1987; Prats <b>et</b> <b>al.</b> 1975; Lopez-Brea <b>et</b> <b>al.</b> 1985; Mirelis <b>et</b> <b>al.</b> 1987; Royo <b>et</b> <b>al.</b> 1993; Mauri <b>et</b> <b>al.</b> 1987; Esparcia <b>et</b> <b>al.</b> 2000; Fernández <b>et</b> <b>al.</b> 2000; Lantero <b>et</b> <b>al.</b> 1984; Folgueira <b>et</b> <b>al.</b> 1991; Fernández-Monrás <b>et</b> <b>al.</b> 1990; Catalá Barceló MT 1998; Fernández-Natal and Alcoba-Leza 1996; Calduch Broseta JV 2003; Rabadan and Vilalta 1989; Rubin <b>et</b> <b>al.</b> 1981; Nedunchezian <b>et</b> <b>al.</b> 1994; Pitrak and Gindorf 1989; Bonner <b>et</b> <b>al.</b> 1983; Newman <b>et</b> <b>al.</b> 1993; Namdari <b>et</b> <b>al.</b> 2000; Patel <b>et</b> <b>al.</b> 2009; Wagner <b>et</b> <b>al.</b> 1995; Siegel and Rogers 1982; McCleskey <b>et</b> <b>al.</b> 1986; Florman <b>et</b> <b>al.</b> 1990; West <b>et</b> <b>al.</b> 1998; Klontz 1990; Hughes <b>et</b> <b>al.</b> 1978; Restrepo <b>et</b> <b>al.</b> 2006; Safrin <b>et</b> <b>al.</b> 1988; Fearrington <b>et</b> <b>al.</b> 1974; Shannon and Kimbrough 2006; Platia and Vosti 1980; Kontoyiannis <b>et</b> <b>al.</b> 1995; Shelton <b>et</b> <b>al.</b> 1993; Crump <b>et</b> <b>al.</b> 2003; Naidu <b>et</b> <b>al.</b> 1993; Morgan <b>et</b> <b>al.</b> 1985; Lukinmaa <b>et</b> <b>al.</b> 2006; Blanche and Sicard 1994; Moinard <b>et</b> <b>al.</b> 1989; Laudat <b>et</b> <b>al.</b> 1997; Raultin and de La Roy, 1981; Couzigou <b>et</b> <b>al.</b> 2007; Issack <b>et</b> <b>al.</b> 2008; Kerketta <b>et</b> <b>al.</b> 2002; Thomas <b>et</b> <b>al.</b> 1996; Lalitha <b>et</b> <b>al.</b> 1986; George <b>et</b> <b>al.</b> 2013; Raju <b>et</b> <b>al.</b> 1990; Khan <b>et</b> <b>al.</b> 2013; Toeg <b>et</b> <b>al.</b> 1990; Rudensky <b>et</b> <b>al.</b> 1993; Farina <b>et</b> <b>al.</b> 1999; Piersimoni <b>et</b> <b>al.</b> 1991; Ismail <b>et</b> <b>al.</b> 2001; Dhar <b>et</b> <b>al.</b> 1989, 2004; Phetsouvanh <b>et</b> <b>al.</b> 2008; Feghali and Adib 2011; Tan <b>et</b> <b>al.</b> 1994; Deris and Leow 2009; Whittaker 2013; Stypulkowska-Misiurewicz <b>et</b> <b>al.</b> 2006; Albuquerque <b>et</b> <b>al.</b> 2013; El-Hiday and Khan 2006; Khan <b>et</b> <b>al.</b> 2007; Strumbelj <b>et</b> <b>al.</b> 2005; Wiström 1989; Lin <b>et</b> <b>al.</b> 1996; Ko <b>et</b> <b>al.</b> 1998; Lee <b>et</b> <b>al.</b> 1993; Chang-Chien 2006; Tsai and Huang 2009; Chan <b>et</b> <b>al.</b> 1994; Yang <b>et</b> <b>al.</b> 2008; Cheng <b>et</b> <b>al.</b> 2004; Tsai <b>et</b> <b>al.</b> 2004; Wang <b>et</b> <b>al.</b> 1991; Laosombat <b>et</b> <b>al.</b> 1996; Punpanich <b>et</b> <b>al.</b> 2011; Thisyakorn and Reinprayoon 1990; Luxsameesathaporn <b>et</b> <b>al.</b> 2012; Suankratay <b>et</b> <b>al.</b> 2001; Wiwatworapan and Insiripong 2008; Boukadida <b>et</b> <b>al.</b> 1993; Lan <b>et</b> <b>al.</b> 2014; Geneste <b>et</b> <b>al.</b> 1995; Yang <b>et</b> <b>al.</b> 2011; Thomas <b>et</b> <b>al.</b> 2007; Ou <b>et</b> <b>al.</b> 2003; Lee <b>et</b> <b>al.</b> 2007; Thamlikitkul 1990; Jesudason <b>et</b> <b>al.</b> 1991). The majority of articles were case reports, the largest series including 69 cases of bacteraemia (Ou <b>et</b> <b>al.</b> 2003). The first case was described in the USA in 1974 (Fearrington <b>et</b> <b>al.</b> 1974). One hundred and fifty-six cases (45  %) originated from Taiwan, 60 / 350 (20  %) from the USA and 21 / 350 (6  %) from Spain. Although NOVC strains are frequently found in coastal waters, only two cases {{have been reported in}} Africa. Two possible explanations are under-diagnosis due to lack of resources, and the non reporting of clinical cases. Including our own case report, 12 cases of NOVC bacteraemia have been published in France, in summer or autumn, including four imported cases from Tunisia (2), Morocco (1) and Senegal (1) (Farmachidi <b>et</b> <b>al.</b> 2003; Blanche and Sicard 1994; Moinard <b>et</b> <b>al.</b> 1989; Laudat <b>et</b> <b>al.</b> 1997; Raultin and de La Roy, 1981; Couzigou <b>et</b> <b>al.</b> 2007).|$|R
30|$|Because of its {{popularity}} for hybrid rice production, both {{the parents and}} the hybrid have been extensively used for genetics and genomics studies during the past four decades. In the first report of resequencing multiple varieties, both parents of SY 63 were used among 20 diverse varieties for resequencing of 100  Mb of the unique fraction of the genome (McNally <b>et</b> <b>al.</b> 2009). It was found that large components of the japonica genome were introgressed into both of the parents, specifically, on chromosome 1 of ZS 97 and chromosome 6 of MH 63. Those components contribute greatly to genes controlling heterosis (Yu <b>et</b> <b>al.</b> 1997; Hua <b>et</b> <b>al.</b> 2002; Li <b>et</b> <b>al.</b> 2008; Li <b>et</b> <b>al.</b> 2008; Zhou <b>et</b> <b>al.</b> 2012; Shen <b>et</b> <b>al.</b> 2014; Zhu <b>et</b> <b>al.</b> 2016). Other studies on the association of QTLs and traits included plant height (Xing <b>et</b> <b>al.</b> 2001; Guo <b>et</b> <b>al.</b> 2002; Yu <b>et</b> <b>al.</b> 2002; Guo <b>et</b> <b>al.</b> 2003; Shen <b>et</b> <b>al.</b> 2014), heading date (Xing <b>et</b> <b>al.</b> 2001; Guo <b>et</b> <b>al.</b> 2002; Guo <b>et</b> <b>al.</b> 2003; Yu <b>et</b> <b>al.</b> 2002; Zhu <b>et</b> <b>al.</b> 2016), fertility-restoring genes (He <b>et</b> <b>al.</b> 2002), seedling traits (Cui <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2010; Zhu <b>et</b> <b>al.</b> 2016), leaf shape (Li <b>et</b> <b>al.</b> 2008), grain quality (Tan <b>et</b> <b>al.</b> 1999; Tan <b>et</b> <b>al.</b> 2001; Xing <b>et</b> <b>al.</b> 2001; Ge <b>et</b> <b>al.</b> 2005; Zheng <b>et</b> <b>al.</b> 2008 a; Zheng <b>et</b> <b>al.</b> 2008 b), yield-related traits (Yu <b>et</b> <b>al.</b> 1997; Guo <b>et</b> <b>al.</b> 2002; Hua <b>et</b> <b>al.</b> 2002; Xing <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2003; Guo <b>et</b> <b>al.</b> 2003; Xue <b>et</b> <b>al.</b> 2008; Li <b>et</b> <b>al.</b> 2008; Xing <b>et</b> <b>al.</b> 2008; Liu <b>et</b> <b>al.</b> 2010; Liu <b>et</b> <b>al.</b> 2010; Zhou <b>et</b> <b>al.</b> 2012), disease resistance (Han <b>et</b> <b>al.</b> 2002; Chen <b>et</b> <b>al.</b> 2002; Yang <b>et</b> <b>al.</b> 2003; Li <b>et</b> <b>al.</b> 2010; Kou <b>et</b> <b>al.</b> 2010), tolerance of nitrogen deficiency (Lian <b>et</b> <b>al.</b> 2005; Wei <b>et</b> <b>al.</b> 2012), and drought tolerance (Lian <b>et</b> <b>al.</b> 2005; Wei <b>et</b> <b>al.</b> 2012).|$|R
30|$|Inter-rater {{reliability}} was reported for 12 (48 %) {{of the studies}} (Barsuk <b>et</b> <b>al.</b> 2009 a; Barsuk <b>et</b> <b>al.</b> 2009 c; Dong <b>et</b> <b>al.</b> 2010; Evans <b>et</b> <b>al.</b> 2009; Huang <b>et</b> <b>al.</b> 2009; Lee <b>et</b> <b>al.</b> 2009; Millington <b>et</b> <b>al.</b> 2009; Murphy <b>et</b> <b>al.</b> 2008; Rosen <b>et</b> <b>al.</b> 2009; Kilbourne <b>et</b> <b>al.</b> 2009; Stone <b>et</b> <b>al.</b> 2010; Xiao <b>et</b> <b>al.</b> 2007), reporting a range of reliability coefficients and absolute agreement [range 0.43 (Millington <b>et</b> <b>al.</b> 2009) to 0.97 (Evans <b>et</b> <b>al.</b> 2009)]. Only 12 studies (48 %) specified the process used for content validation (Velmahos <b>et</b> <b>al.</b> 2004; Barsuk <b>et</b> <b>al.</b> 2009 a; Barsuk <b>et</b> <b>al.</b> 2009 c; Costello <b>et</b> <b>al.</b> 2008; Dong <b>et</b> <b>al.</b> 2010; Evans <b>et</b> <b>al.</b> 2009; Huang <b>et</b> <b>al.</b> 2009; Lee <b>et</b> <b>al.</b> 2009; Rosen <b>et</b> <b>al.</b> 2009; Wall <b>et</b> <b>al.</b> 2005; Kilbourne <b>et</b> <b>al.</b> 2009; Coopersmith <b>et</b> <b>al.</b> 2002).|$|R
30|$|To sputter calcium orthophosphates, {{several types}} of the {{physical}} vapor deposition techniques are used, such as ion beam (Stevenson <b>et</b> <b>al.</b> 1989; Barthell <b>et</b> <b>al.</b> 1989; Ong <b>et</b> <b>al.</b> 1991, 1992, 1994; Yoshinari <b>et</b> <b>al.</b> 1994; Cui <b>et</b> <b>al.</b> 1997; Kim <b>et</b> <b>al.</b> 1998; Luo <b>et</b> <b>al.</b> 1999; Choi <b>et</b> <b>al.</b> 2000; Wang <b>et</b> <b>al.</b> 2001; Hamdi and Ide-Ektessabi 2003; Lee <b>et</b> <b>al.</b> 2003; Fujihara <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2005 b; Rabiei <b>et</b> <b>al.</b> 2006; Lee <b>et</b> <b>al.</b> 2007 a; Blalock <b>et</b> <b>al.</b> 2007), radio-frequency (RF) magnetron (Cooley <b>et</b> <b>al.</b> 1992; Yamashita <b>et</b> <b>al.</b> 1994; Jansen <b>et</b> <b>al.</b> 1993; Wolke <b>et</b> <b>al.</b> 1994; van Dijk <b>et</b> <b>al.</b> 1995, 1996; Wolke <b>et</b> <b>al.</b> 1998, 2003; Nelea <b>et</b> <b>al.</b> 2003, 2004; Feddes <b>et</b> <b>al.</b> 2003 a, 2003 b; Ding 2003; Yamaguchi <b>et</b> <b>al.</b> 2006; Wan <b>et</b> <b>al.</b> 2007; Ozeki <b>et</b> <b>al.</b> 2007; Ueda <b>et</b> <b>al.</b> 2007; Snyders <b>et</b> <b>al.</b> 2008; Ievlev <b>et</b> <b>al.</b> 2008; Toque <b>et</b> <b>al.</b> 2009), pulsed laser (Nelea <b>et</b> <b>al.</b> 2000, 2002, 2004; Cotell <b>et</b> <b>al.</b> 1992, Cotell 1993; Torrisi and Setola 1993; Cotell 1993; Singh <b>et</b> <b>al.</b> 1994; Wang <b>et</b> <b>al.</b> 1997; Hontsu <b>et</b> <b>al.</b> 1997; Fernández-Pradas <b>et</b> <b>al.</b> 1998, 1999, 2001; Mayor <b>et</b> <b>al.</b> 1998; Arias <b>et</b> <b>al.</b> 1998; Craciun <b>et</b> <b>al.</b> 1999; Fernandez-Pradas <b>et</b> <b>al.</b> 1999; Zeng <b>et</b> <b>al.</b> 2000; Cleries <b>et</b> <b>al.</b> 2000 a; Nelea <b>et</b> <b>al.</b> 2000; Zeng and Lacefield 2000; Fernandez-Pradas <b>et</b> <b>al.</b> 2001; Nelea <b>et</b> <b>al.</b> 2002; Socol <b>et</b> <b>al.</b> 2004; Kim <b>et</b> <b>al.</b> 2005 a; Bigi <b>et</b> <b>al.</b> 2005 b; Koch <b>et</b> <b>al.</b> 2007; Kim <b>et</b> <b>al.</b> 2007 a; Paital and Dahotre 2008; Paital <b>et</b> <b>al.</b> 2009; Dinda <b>et</b> <b>al.</b> 2009; Tri and Chua 2009; Sygnatowicz and Tiwari 2009), diode, direct current and reactive sputtering or deposition (Massaro <b>et</b> <b>al.</b> 2001). The physical and aggregate states of the calcium orthophosphate source might influence the deposition kinetics. For example, the deposition rate of HA {{was found to be}} much higher in a solid plate target than in a powder lump target, owing to the difference of apparent density approximately 75 % and approximately 18 %, respectively (Wan <b>et</b> <b>al.</b> 2007).|$|R
30|$|Recently, genetic {{studies of}} IPMN lead to {{discover}} mutations of new genes, including GNAS, and RNF 43 (Macgregor-Das and Iacobuzio-Donahue 2013; Reid <b>et</b> <b>al.</b> 2014). In {{addition to the}} previously known genetic alteration such as KRAS, these gene mutations open a new viewpoint {{in the field of}} the molecular pathogenesis of IPMN. Nevertheless, the frequencies and clinicopathologic significances of KRAS, GNAS, and RNF 43 have not been clearly delineated. Activating GNAS mutation at codon 201 has been identified in IPMNs of the pancreas, which runs from 36 to 79  % (Amato <b>et</b> <b>al.</b> 2014; Hosoda <b>et</b> <b>al.</b> 2015; Ideno <b>et</b> <b>al.</b> 2015; Kanda <b>et</b> <b>al.</b> 2013; Kuboki <b>et</b> <b>al.</b> 2015; Lee <b>et</b> <b>al.</b> 2014; Siddiqui <b>et</b> <b>al.</b> 2013; Singhi <b>et</b> <b>al.</b> 2014; Takano <b>et</b> <b>al.</b> 2014; Tan <b>et</b> <b>al.</b> 2015; Wu <b>et</b> <b>al.</b> 2011 b). Moreover, the wide extreme diversity of KRAS mutation in IPMN patients, ranged from 13 to 100  %, has been observed (Amato <b>et</b> <b>al.</b> 2014; Chadwick <b>et</b> <b>al.</b> 2009; Chang <b>et</b> <b>al.</b> 2014; Fritz <b>et</b> <b>al.</b> 2009; Furukawa <b>et</b> <b>al.</b> 2005; Hosoda <b>et</b> <b>al.</b> 2015; Ideno <b>et</b> <b>al.</b> 2015; Jang <b>et</b> <b>al.</b> 2009; Kaino <b>et</b> <b>al.</b> 1999; Kitago <b>et</b> <b>al.</b> 2004; Kobayashi <b>et</b> <b>al.</b> 2008; Kondo <b>et</b> <b>al.</b> 1997; Kuboki <b>et</b> <b>al.</b> 2015; Lee <b>et</b> <b>al.</b> 2014; Lubezky <b>et</b> <b>al.</b> 2011; Mizuno <b>et</b> <b>al.</b> 2010; Mohri <b>et</b> <b>al.</b> 2012; Mueller <b>et</b> <b>al.</b> 2003; Mulligan <b>et</b> <b>al.</b> 1999; Nakata <b>et</b> <b>al.</b> 2002; Paal <b>et</b> <b>al.</b> 1999; Raimondo <b>et</b> <b>al.</b> 2002; Schönleben <b>et</b> <b>al.</b> 2008; Sessa <b>et</b> <b>al.</b> 1994; Siddiqui <b>et</b> <b>al.</b> 2013; Singhi <b>et</b> <b>al.</b> 2014; Tada <b>et</b> <b>al.</b> 1991; Takano <b>et</b> <b>al.</b> 2014; Tan <b>et</b> <b>al.</b> 2015; Uemura <b>et</b> <b>al.</b> 2003; Wada <b>et</b> <b>al.</b> 2004; Wu <b>et</b> <b>al.</b> 2011 b; Yoshizawa <b>et</b> <b>al.</b> 2002). The frequency of RNF 43 mutation was ranged from 14 to 75  % (Amato <b>et</b> <b>al.</b> 2014; Sakamoto <b>et</b> <b>al.</b> 2015; Tan <b>et</b> <b>al.</b> 2015; Wu <b>et</b> <b>al.</b> 2011 a).|$|R
30|$|The donor-sites {{used for}} the {{osteochondral}} graft harvesting varied across the studies, including: margins of the medial femoral trochlea (condyle) (Hangody <b>et</b> <b>al.</b> 2010; Gudas <b>et</b> <b>al.</b> 2005; Ahmad & Jones 2015; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014); margins of the lateral femoral trochlea (condyle) (Hangody <b>et</b> <b>al.</b> 2010; Reddy <b>et</b> <b>al.</b> 2007; Gudas <b>et</b> <b>al.</b> 2005; Ahmad & Jones 2015; Al-Shaikh <b>et</b> <b>al.</b> 2002; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009); minimal weight-bearing areas of the patellofemoral joint (Atik <b>et</b> <b>al.</b> 2005); intercondylar notch area (Reddy <b>et</b> <b>al.</b> 2007; Atik <b>et</b> <b>al.</b> 2005; Hangody <b>et</b> <b>al.</b> 2008); upper tibio-fibular joint (Espregueira-Mendes <b>et</b> <b>al.</b> 2012).|$|R
30|$|The {{selenium}} nanoparticles are bestowed with multifaceted biological properties mainly due {{its high}} bioavailability and biocompatibility; and low cytotoxicity (Shakibaie <b>et</b> <b>al.</b> 2010; Wang <b>et</b> <b>al.</b> 2010, 2013). A {{wide variety of}} properties shown by selenium nanoparticles are free radical scavenging (Huang <b>et</b> <b>al.</b> 2003), antioxidant (Forootanfar <b>et</b> <b>al.</b> 2014; Kong <b>et</b> <b>al.</b> 2014; Mittal <b>et</b> <b>al.</b> 2014; Ramya <b>et</b> <b>al.</b> 2015; Rezvanfar <b>et</b> <b>al.</b> 2013; Torres <b>et</b> <b>al.</b> 2012; Wang <b>et</b> <b>al.</b> 2013), chemoprotection against chemotherapy-induced reproductive toxicity (Rezvanfar <b>et</b> <b>al.</b> 2013) and UV-induced DNA damage (Prasad <b>et</b> <b>al.</b> 2013), immunomodulatory, anti-inflammatory (Wang <b>et</b> <b>al.</b> 2014), nanomedicinal (Shen <b>et</b> <b>al.</b> 2008), chemotherapeutic and chemoprevention against human melanoma and hepatoma cancers (Chen <b>et</b> <b>al.</b> 2008; Estevez <b>et</b> <b>al.</b> 2014; Peng <b>et</b> <b>al.</b> 2007), biofortification (Durán <b>et</b> <b>al.</b> 2015), and antitumor and anticancer (Jia <b>et</b> <b>al.</b> 2015; Kumar <b>et</b> <b>al.</b> 2015; Mittal <b>et</b> <b>al.</b> 2014; Ren <b>et</b> <b>al.</b> 2013) activities. Other applications include antibacterial, antibiofilm (Bartůněk <b>et</b> <b>al.</b> 2015; Hariharan <b>et</b> <b>al.</b> 2012; Huang <b>et</b> <b>al.</b> 2016; Mittal <b>et</b> <b>al.</b> 2014; Ramya <b>et</b> <b>al.</b> 2015; Shakibaie <b>et</b> <b>al.</b> 2015; Tran and Webster 2011; Wang and Webster 2013), antifungal, antiprotozoan, antitapeworm (Bartůněk <b>et</b> <b>al.</b> 2015), antiviral, wound healing (Ramya <b>et</b> <b>al.</b> 2015), and cytotoxic (Forootanfar <b>et</b> <b>al.</b> 2014; Ramya <b>et</b> <b>al.</b> 2015) activities. Other non-biological activities such as zinc adsorption (Jain <b>et</b> <b>al.</b> 2015), mercury sequestration (Fellowes <b>et</b> <b>al.</b> 2011; Jiang <b>et</b> <b>al.</b> 2012), biosensing of H 2 O 2 (Wang <b>et</b> <b>al.</b> 2010), solar cell (Panahi-Kalamuei <b>et</b> <b>al.</b> 2014), and photocatalysis (Triantis <b>et</b> <b>al.</b> 2009; Yang <b>et</b> <b>al.</b> 2008) are also reported.|$|R
30|$|Although breast {{reconstruction}} {{rates have}} increased over time, they remain relatively low, ranging from 5 to 42  % in population-based and institution-based studies (Brennan and Spillane 2013; Platt <b>et</b> <b>al.</b> 2011; Wilkins and Alderman 2004). These {{studies have found}} that reconstruction rates are significantly lower in African American compared to Caucasian women (Alderman <b>et</b> <b>al.</b> 2009, 2011; Butler <b>et</b> <b>al.</b> 2015; Greenberg <b>et</b> <b>al.</b> 2008; Hershman <b>et</b> <b>al.</b> 2012; Katz <b>et</b> <b>al.</b> 2005; Merchant <b>et</b> <b>al.</b> 2015; Morrow <b>et</b> <b>al.</b> 2005; Reuben <b>et</b> <b>al.</b> 2009; Rosson <b>et</b> <b>al.</b> 2008; Rowland <b>et</b> <b>al.</b> 2000; Tseng <b>et</b> <b>al.</b> 2004; Yang <b>et</b> <b>al.</b> 2013 a, b), a disparity that has been attributed to racial differences in access to breast reconstructive services (Agarwal <b>et</b> <b>al.</b> 2011; Enewold <b>et</b> <b>al.</b> 2014; Greenberg <b>et</b> <b>al.</b> 2008; Katz <b>et</b> <b>al.</b> 2005; Offodile <b>et</b> <b>al.</b> 2015; Rowland <b>et</b> <b>al.</b> 1993; Wexelman <b>et</b> <b>al.</b> 2014) secondary to lower socioeconomic status (Alderman <b>et</b> <b>al.</b> 2003; Greenberg <b>et</b> <b>al.</b> 2008; Joslyn 2005; Katz <b>et</b> <b>al.</b> 2005; Kruper <b>et</b> <b>al.</b> 2011 a; Offodile <b>et</b> <b>al.</b> 2015; Wexelman <b>et</b> <b>al.</b> 2014) and no or inadequate insurance (Alderman <b>et</b> <b>al.</b> 2006; Bradley <b>et</b> <b>al.</b> 2012; Enewold <b>et</b> <b>al.</b> 2014; Wexelman <b>et</b> <b>al.</b> 2014).|$|R
30|$|High {{rates of}} co-occurrence of bipolar {{disorder}} (BD) and eating disorders (EDs) are well documented (Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2011, 2013, 2016; Wildes <b>et</b> <b>al.</b> 2008). EDs are more prevalent among females compared to males with BD (Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2011, 2016; Seixas <b>et</b> <b>al.</b> 2012) {{and have been}} associated with more challenging bipolar course, including earlier onset age (Brietzke <b>et</b> <b>al.</b> 2011; Jen <b>et</b> <b>al.</b> 2013; Lunde <b>et</b> <b>al.</b> 2009; McElroy <b>et</b> <b>al.</b> 2011, 2016), more depressive and mood episodes (Brietzke <b>et</b> <b>al.</b> 2011; Lunde <b>et</b> <b>al.</b> 2009; McElroy <b>et</b> <b>al.</b> 2011), rapid cycling (Fornaro <b>et</b> <b>al.</b> 2010; McElroy <b>et</b> <b>al.</b> 2011, 2016), depressive symptoms (Jen <b>et</b> <b>al.</b> 2013; Seixas <b>et</b> <b>al.</b> 2012; Wildes <b>et</b> <b>al.</b> 2007, 2008), suicide attempts (Brietzke <b>et</b> <b>al.</b> 2011; McElroy <b>et</b> <b>al.</b> 2011, 2013, 2016), weight disturbance (McElroy <b>et</b> <b>al.</b> 2011, 2013, 2016; Wildes <b>et</b> <b>al.</b> 2007, 2008), and psychiatric comorbidities (Seixas <b>et</b> <b>al.</b> 2012), including lifetime anxiety (Brietzke <b>et</b> <b>al.</b> 2011; Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2013, 2016) and alcohol/substance use disorders (Brietzke <b>et</b> <b>al.</b> 2011; Fornaro <b>et</b> <b>al.</b> 2010; Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2013).|$|R
30|$|The {{production}} of lignolytic enzymes and its regulation has been intensively studied in various lignin degrading fungi (Bonnarme &Jeffries 1990;Hakala <b>et</b> <b>al.</b> 2006; Jiménez-Tobon <b>et</b> <b>al.</b> 2003;Kamitsuji <b>et</b> <b>al.</b> 2004;Lankinen <b>et</b> <b>al.</b> 2005; Martínez <b>et</b> <b>al.</b> 1996;Moilanen <b>et</b> <b>al.</b> 1996;Nuske <b>et</b> <b>al.</b> 2002; Perie &Gold 1991;Palma <b>et</b> <b>al.</b> 2000;Petruccioli <b>et</b> <b>al.</b> 2009;Schneegab <b>et</b> <b>al.</b> 1997; Swamy &Ramsay 1999;Steffen <b>et</b> <b>al.</b> 2002;Susla <b>et</b> <b>al.</b> 2008;Silva <b>et</b> <b>al.</b> 2008;Sklenar <b>et</b> <b>al.</b> 2010;Singh <b>et</b> <b>al.</b> 2011; Taboada-Puig <b>et</b> <b>al.</b> 2011;Vares <b>et</b> <b>al.</b> 1995;Wang <b>et</b> <b>al.</b> 2001;Wang <b>et</b> <b>al.</b> 2008) and novel bacterial strains (Bharagava <b>et</b> <b>al.</b> 2009; Mishra &Thakur 2010;Yadav <b>et</b> <b>al.</b> 2011). Recombinant production {{has been studied}} in filamentous fungi (Conesa <b>et</b> <b>al.</b> 2000;Irie <b>et</b> <b>al.</b> 2001;Li <b>et</b> <b>al.</b> 2001;Mayfield <b>et</b> <b>al.</b> 1994;Stewart <b>et</b> <b>al.</b> 1996), yeasts (Jiang <b>et</b> <b>al.</b> 2008 a), bacterial (Whitwam &Tien 1996) and insect (Johnson <b>et</b> <b>al.</b> 1992; Pease <b>et</b> <b>al.</b> 1991) hosts with successful production but modest yields of active enzyme. MnP from P. chrysosporium has {{been the target of}} most recombinant studies, which however suffer from unsuccessful posttranslational protein modification and the need for exogenous heme in high concentrations (Jiang <b>et</b> <b>al.</b> 2008 a).|$|R
30|$|Proteasome phosphorylations {{are seen}} in almost every {{large-scale}} phosphoproteomic dataset. More importantly, the proteasome is dynamically phosphorylated {{in a variety of}} physiological and pathological processes, including development and stem/progenitor cell differentiation (Brill <b>et</b> <b>al.,</b> 2009; Rigbolt <b>et</b> <b>al.,</b> 2011; Goswami <b>et</b> <b>al.,</b> 2012), cell cycle (Beausoleil <b>et</b> <b>al.,</b> 2006; Dephoure <b>et</b> <b>al.,</b> 2008; Nagano <b>et</b> <b>al.,</b> 2009; Olsen <b>et</b> <b>al.,</b> 2010; Kettenbach <b>et</b> <b>al.,</b> 2011; Guo <b>et</b> <b>al.,</b> 2016), DNA damage response (Matsuoka <b>et</b> <b>al.,</b> 2007; Stokes <b>et</b> <b>al.,</b> 2007), stress responses (Um <b>et</b> <b>al.,</b> 2010; Wang <b>et</b> <b>al.,</b> 2014), immune signaling (Bose <b>et</b> <b>al.,</b> 2001; Bose <b>et</b> <b>al.,</b> 2004; Mayya <b>et</b> <b>al.,</b> 2009; Weintz <b>et</b> <b>al.,</b> 2010; Wu <b>et</b> <b>al.,</b> 2012), metabolic changes (Bardag-Gorce <b>et</b> <b>al.,</b> 2004; Zhang <b>et</b> <b>al.,</b> 2007 b; Trost <b>et</b> <b>al.,</b> 2012), neuronal activity (Djakovic <b>et</b> <b>al.,</b> 2009; Bingol <b>et</b> <b>al.,</b> 2010; Djakovic <b>et</b> <b>al.,</b> 2012; Hamilton <b>et</b> <b>al.,</b> 2012; Jarome <b>et</b> <b>al.,</b> 2013; Jarome <b>et</b> <b>al.,</b> 2016; Li <b>et</b> <b>al.,</b> 2016), hormones and growth factor signaling (Kim <b>et</b> <b>al.,</b> 2009; Pan <b>et</b> <b>al.,</b> 2009; Lundby <b>et</b> <b>al.,</b> 2013; Williams <b>et</b> <b>al.,</b> 2016), and oncogenesis (Rush <b>et</b> <b>al.,</b> 2005; Rikova <b>et</b> <b>al.,</b> 2007; Guo <b>et</b> <b>al.,</b> 2008; Luo <b>et</b> <b>al.,</b> 2008; Choudhary <b>et</b> <b>al.,</b> 2009; Eang <b>et</b> <b>al.,</b> 2009; Iliuk <b>et</b> <b>al.,</b> 2010; Johnson <b>et</b> <b>al.,</b> 2012; Trost <b>et</b> <b>al.,</b> 2012; Yuan <b>et</b> <b>al.,</b> 2013). Although the functional roles of proteasome phosphorylation in these processes are largely uncharacterized, increasing evidence indicates that the 26 S proteasome is not a uniform and static complex acting passively as a “cellular trashcan”. Rather, the proteasome itself is fine-tuned by reversible phosphorylation in response to intra- and extra-cellular signals, which can be a prerequisite or feedback mechanism for a wide spectrum of cellular events that depend on proteasome function.|$|R
30|$|Hand, foot, {{and mouth}} disease is {{commonly}} caused by CA 16 and EV 71 with typical lesions on the hands, feet, mouth, buttock, elbows and knees (Chatproedprai <b>et</b> <b>al.</b> 2010; Hubiche <b>et</b> <b>al.</b> 2014). CA 6 {{emerged as a}} large scale outbreak in Thailand in 2012 and continued {{to be one of}} the major causes of HFMD worldwide (Wei <b>et</b> <b>al.</b> 2011; Flett <b>et</b> <b>al.</b> 2012; Fujimoto <b>et</b> <b>al.</b> 2012; Chung <b>et</b> <b>al.</b> 2013; Kaminska <b>et</b> <b>al.</b> 2013; Lott <b>et</b> <b>al.</b> 2013; Ben-Chetrit <b>et</b> <b>al.</b> 2014; Feder <b>et</b> <b>al.</b> 2014; Hubiche <b>et</b> <b>al.</b> 2014; Li <b>et</b> <b>al.</b> 2014; Sinclair <b>et</b> <b>al.</b> 2014). Unusual manifestations include widespread vesiculobullous and erosive lesions extending beyond the palms and soles (Wei <b>et</b> <b>al.</b> 2011; Chung <b>et</b> <b>al.</b> 2013; Kobayashi <b>et</b> <b>al.</b> 2013; Lott <b>et</b> <b>al.</b> 2013; Mathes <b>et</b> <b>al.</b> 2013; Feder <b>et</b> <b>al.</b> 2014; Hubiche <b>et</b> <b>al.</b> 2014) including dorsal sides of the hands and feet (Flett <b>et</b> <b>al.</b> 2012; Feder <b>et</b> <b>al.</b> 2014), calves and trunk (Feder <b>et</b> <b>al.</b> 2014), eczema herpeticum-like eruption termed “eczema coxsackium” (Mathes <b>et</b> <b>al.</b> 2013; Akkoyunlu <b>et</b> <b>al.</b> 2014; Sinclair <b>et</b> <b>al.</b> 2014), eruption similar to GCS (Mathes <b>et</b> <b>al.</b> 2013), petechiae or purpuric eruption (Mathes <b>et</b> <b>al.</b> 2013; Stewart <b>et</b> <b>al.</b> 2013), varicelliform (Yasui <b>et</b> <b>al.</b> 2013; Sinclair <b>et</b> <b>al.</b> 2014), delayed desquamation of palms and soles (Wei <b>et</b> <b>al.</b> 2011; Mathes <b>et</b> <b>al.</b> 2013), and onychomadesis (transient separation of proximal nail plate) during convalescence (Wei <b>et</b> <b>al.</b> 2011; Feder <b>et</b> <b>al.</b> 2014).|$|R
30|$|Although few {{previous}} {{reports have}} shown the characteristics of imaging findings of primary hepatic carcinoid tumors owing to their rarity, it has been thought, based on previous reports and our present cases, that the relatively characteristic imaging findings include cystic areas with hemorrhagic components (Takayasu <b>et</b> <b>al.</b> 1992; Abdel Wahab <b>et</b> <b>al.</b> 2006; Komatsuda <b>et</b> <b>al.</b> 2005; Ulusan <b>et</b> <b>al.</b> 2005; Touloumis <b>et</b> <b>al.</b> 2008; Imaoka <b>et</b> <b>al.</b> 1993; Fujino <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998; Kehagias <b>et</b> <b>al.</b> 1999; Hirata <b>et</b> <b>al.</b> 2002; Aoki <b>et</b> <b>al.</b> 1992; Yeung <b>et</b> <b>al.</b> 2008; Shih <b>et</b> <b>al.</b> 2005) and early enhanced solid areas (Iwao <b>et</b> <b>al.</b> 2001; Lin <b>et</b> <b>al.</b> 2009; Takayasu <b>et</b> <b>al.</b> 1992; Abdel Wahab <b>et</b> <b>al.</b> 2006; Komatsuda <b>et</b> <b>al.</b> 2005; Ulusan <b>et</b> <b>al.</b> 2005; Touloumis <b>et</b> <b>al.</b> 2008; Iimuro <b>et</b> <b>al.</b> 2002; Gao J <b>et</b> <b>al.</b> 2011; Shah <b>et</b> <b>al.</b> 2007).|$|R
30|$|Many {{factors have}} been {{identified}} that seem to impact {{the mental health of}} populations affected by natural disasters, which contribute to the onset and severity of posttraumatic stress disorder (PTSD): female gender (Carr <b>et</b> <b>al.</b> 1995; Karanci and Rustemli 1995; Sharan <b>et</b> <b>al.</b> 1996; C. C. Chen <b>et</b> <b>al.</b> 2001; Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003; Kiliç and Ulusoy 2003; Chang <b>et</b> <b>al.</b> 2005; Montazeri <b>et</b> <b>al.</b> 2005; Sattler <b>et</b> <b>al.</b> 2006; Hansson <b>et</b> <b>al.</b> 1994; C. H. Chen <b>et</b> <b>al.</b> 2007; Kuwabara <b>et</b> <b>al.</b> 2008; Priebe <b>et</b> <b>al.</b> 2009; Steel <b>et</b> <b>al.</b> 2011; Ahmad <b>et</b> <b>al.</b> 2010; Dell'Osso <b>et</b> <b>al.</b> 2011 b; Zhang and Ho 2011), older (Carr <b>et</b> <b>al.</b> 1997; Salcioglu <b>et</b> <b>al.</b> 2003; Toyabe <b>et</b> <b>al.</b> 2006; C. H. Chen <b>et</b> <b>al.</b> 2007; Priebe <b>et</b> <b>al.</b> 2009; Zhang and Ho 2011) or younger age at trauma (Kato <b>et</b> <b>al.</b> 1996), lower education (Karanci and Rustemli 1995; Armenian <b>et</b> <b>al.</b> 2000; Basoglu <b>et</b> <b>al.</b> 2002; Kiliç and Ulusoy 2003; Montazeri <b>et</b> <b>al.</b> 2005; C. H. Chen <b>et</b> <b>al.</b> 2007; Priebe <b>et</b> <b>al.</b> 2009; Wang <b>et</b> <b>al.</b> 2009; Ahmad <b>et</b> <b>al.</b> 2010), epigenetic vulnerability (Broekman <b>et</b> <b>al.</b> 2007; Mehta and Binder 2012), previous psychiatric illness (Nolen-Hoeksema and Morrow 1991; Basoglu <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003), fear of death {{at the time of the}} disaster (Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Bergiannaki <b>et</b> <b>al.</b> 2003; Salcioglu <b>et</b> <b>al.</b> 2003; Kiliç and Ulusoy 2003; Basoglu <b>et</b> <b>al.</b> 2004; Kuwabara <b>et</b> <b>al.</b> 2008), degree of exposure to the disaster (Goenjian <b>et</b> <b>al.</b> 1994; Carr <b>et</b> <b>al.</b> 1995; Armenian <b>et</b> <b>al.</b> 2000; Sattler <b>et</b> <b>al.</b> 2006; Wang <b>et</b> <b>al.</b> 2009; Zhang and Ho 2011), closer proximity to the epicenter of an earthquake (Ahmad <b>et</b> <b>al.</b> 2010), loss of loved ones (Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Montazeri <b>et</b> <b>al.</b> 2005; Goenjian <b>et</b> <b>al.</b> 1994; Dell'Osso <b>et</b> <b>al.</b> 2011 a), property or resource loss (Freedy <b>et</b> <b>al.</b> 1994; Armenian <b>et</b> <b>al.</b> 2000; C. C. Chen <b>et</b> <b>al.</b> 2001; Bland <b>et</b> <b>al.</b> 2005; Sattler <b>et</b> <b>al.</b> 2006; C. H. Chen <b>et</b> <b>al.</b> 2007; Kuwabara <b>et</b> <b>al.</b> 2008; Sharan <b>et</b> <b>al.</b> 1996), having been trapped/injured under rubble and/or participation in rescue work (Basoglu <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003; Kuwabara <b>et</b> <b>al.</b> 2008; Ehring <b>et</b> <b>al.</b> 2011), greater number of traumatic experiences (Chang <b>et</b> <b>al.</b> 2005), relocation after a disaster (Najarian <b>et</b> <b>al.</b> 2001; Kiliç <b>et</b> <b>al.</b> 2006), less social support (Bland <b>et</b> <b>al.</b> 1997; Armenian <b>et</b> <b>al.</b> 2000; Sattler <b>et</b> <b>al.</b> 2006; Bland <b>et</b> <b>al.</b> 2005; Wang <b>et</b> <b>al.</b> 2009), and diminished individual coping (Olff <b>et</b> <b>al.</b> 2005). Within one month after exposure to an extreme traumatic stressor, a mental disorder, such as acute stress disorder (ASD) can manifest. ASD is characterized by the development of dissociative and re-experiencing of symptoms, marked avoidance, anxiety or increased arousal, and significant distress or functional impairment. A diagnosis of ASD seems to have predictive power for PTSD by reducing the number of symptoms required within the dissociative cluster criteria, identifying subsyndromal ASD (Bryant 2011).|$|R
30|$|PNPLA 3 polymorphisms {{have been}} {{reported}} to be associated with hepatic steatosis, inflammation, fibrosis, and carcinogenesis in NAFLD (Romeo <b>et</b> <b>al.</b> 2008; Rotman <b>et</b> <b>al.</b> 2010; Valenti <b>et</b> <b>al.</b> 2010; Sookoian and Pirola 2011; Burza <b>et</b> <b>al.</b> 2012; Kawaguchi <b>et</b> <b>al.</b> 2012; Kitamoto <b>et</b> <b>al.</b> 2013). PNPLA 3 polymorphisms have also been reported to be associated with hepatic steatosis, fibrosis, treatment response, and carcinogenesis in CHC (Valenti <b>et</b> <b>al.</b> 2011; Trepo <b>et</b> <b>al.</b> 2011; Cai <b>et</b> <b>al.</b> 2011; Valenti <b>et</b> <b>al.</b> 2012; Clark <b>et</b> <b>al.</b> 2012; Dunn <b>et</b> <b>al.</b> 2014; Ezzikouri <b>et</b> <b>al.</b> 2014; Moritou <b>et</b> <b>al.</b> 2013; Zampino <b>et</b> <b>al.</b> 2013; Trepo <b>et</b> <b>al.</b> 2014; Sato <b>et</b> <b>al.</b> 2013). However, several reports have not found an association of PNPLA 3 polymorphisms with fibrosis and carcinogenesis in CHC (Trepo <b>et</b> <b>al.</b> 2011; Nischalke <b>et</b> <b>al.</b> 2011; Rembeck <b>et</b> <b>al.</b> 2012; Miyashita <b>et</b> <b>al.</b> 2012; Takeuchi <b>et</b> <b>al.</b> 2013; Nakamura <b>et</b> <b>al.</b> 2013; Guyot <b>et</b> <b>al.</b> 2013).|$|R
30|$|Epidemiological {{studies on}} the {{association}} between physical activity and mammographic density have reported inconsistent results (Lopez <b>et</b> <b>al.</b> 2003; Monninkhof <b>et</b> <b>al.</b> 2007; Irwin <b>et</b> <b>al.</b> 2006; Masala <b>et</b> <b>al.</b> 2009; Siozon <b>et</b> <b>al.</b> 2006; Gram <b>et</b> <b>al.</b> 1999; Suijkerbuijk <b>et</b> <b>al.</b> 2006; Reeves <b>et</b> <b>al.</b> 2007; Samimi <b>et</b> <b>al.</b> 2008; Conroy <b>et</b> <b>al.</b> 2010; Peters <b>et</b> <b>al.</b> 2008). A few have reported a statistically significant inverse association between physical activity and mammographic density (Masala <b>et</b> <b>al.</b> 2009; Lopez <b>et</b> <b>al.</b> 2003; Irwin <b>et</b> <b>al.</b> 2006; Monninkhof <b>et</b> <b>al.</b> 2007). But most studies have {{found no evidence of}} an association (Peters <b>et</b> <b>al.</b> 2008; Suijkerbuijk <b>et</b> <b>al.</b> 2006; Siozon <b>et</b> <b>al.</b> 2006; Reeves <b>et</b> <b>al.</b> 2007; Samimi <b>et</b> <b>al.</b> 2008; Conroy <b>et</b> <b>al.</b> 2010; Gram <b>et</b> <b>al.</b> 1999). A number of these studies have reported a positive association between physical activity and mammographic density that attenuated after adjustments for BMI (Peters <b>et</b> <b>al.</b> 2008; Reeves <b>et</b> <b>al.</b> 2007).|$|R
30|$|Recently, the risk-benefit {{ratio of}} HT was reassessed for various ages and time {{intervals}} since menopause onset. The North American Menopause Society (NAMS) (NAMS 2012) proposed that {{duration of treatment}} {{should be limited to}} younger women up to the age of 50 to 59 years; beyond which, HT is associated with increased risks. Similar recommendations were issued by the International Menopause Society (IMS) in 2011 (Sturdee <b>et</b> <b>al.</b> 2011), which considered HT as a first-line therapy choice for climacteric symptoms. Finally, a global consensus on the use of HT was obtained by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society (de Villiers <b>et</b> <b>al.</b> 2013). They stated that HT “is the most effective treatment for vasomotor symptoms associated with menopause at any age, but benefits are more likely to outweigh risks for symptomatic women before the age of 60 years or within 10 years after menopause”. Although some HT restrictions have been withdrawn, there is still a considerable need for non-hormonal treatment alternatives, especially for elderly post-menopausal women or cancer patients of both genders. Therefore, this present work aimed to assess the risk-benefit ratio of various non-hormonal treatment options. Among them, four non-hormonal treatments appear to have significant evidence for a beneficial effect in treating vasomotor climacteric or androgen-ablation symptoms, although some studied the effects over a period shorter than 12 weeks: gabapentin/pregabalin (Loprinzi <b>et</b> <b>al.</b> 2002 a; Guttuso <b>et</b> <b>al.</b> 2003; Reddy <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 2007; Butt <b>et</b> <b>al.</b> 2008; Saadati <b>et</b> <b>al.</b> 2013; Agarwal <b>et</b> <b>al.</b> 2014; Pinkerton <b>et</b> <b>al.</b> 2014; Loprinzi <b>et</b> <b>al.</b> 2010; Pandya <b>et</b> <b>al.</b> 2004; Pandya <b>et</b> <b>al.</b> 2005; Bordeleau <b>et</b> <b>al.</b> 2010; Loprinzi <b>et</b> <b>al.</b> 2009; Moraska <b>et</b> <b>al.</b> 2010), SSRIs (Stearns <b>et</b> <b>al.</b> 2003; Stearns <b>et</b> <b>al.</b> 2005; Simon <b>et</b> <b>al.</b> 2013; Huang <b>et</b> <b>al.</b> 2013; Stearns <b>et</b> <b>al.</b> 2000; Gordon <b>et</b> <b>al.</b> 2006; Grady <b>et</b> <b>al.</b> 2007; Kerwin <b>et</b> <b>al.</b> 2007; Aedo <b>et</b> <b>al.</b> 2011; Kimmick <b>et</b> <b>al.</b> 2006; Wu <b>et</b> <b>al.</b> 2009; Suvanto-Luukkonen <b>et</b> <b>al.</b> 2005; Oktem <b>et</b> <b>al.</b> 2007; Loprinzi <b>et</b> <b>al.</b> 2002 b; Barton <b>et</b> <b>al.</b> 2010; Barton <b>et</b> <b>al.</b> 2003; Defronzo Dobkin <b>et</b> <b>al.</b> 2009; Freedman <b>et</b> <b>al.</b> 2011; Freeman <b>et</b> <b>al.</b> 2011; Carpenter <b>et</b> <b>al.</b> 2012; Ensrud <b>et</b> <b>al.</b> 2012), venlafaxine/desvenlafaxine (Evans <b>et</b> <b>al.</b> 2005; Loprinzi <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 1998; Carpenter <b>et</b> <b>al.</b> 2007; Quella <b>et</b> <b>al.</b> 1999; Loprinzi <b>et</b> <b>al.</b> 2000; Loibl <b>et</b> <b>al.</b> 2007; Buijs <b>et</b> <b>al.</b> 2009; Boekhout <b>et</b> <b>al.</b> 2011; Bordeleau <b>et</b> <b>al.</b> 2010; Vitolins <b>et</b> <b>al.</b> 2013; Speroff <b>et</b> <b>al.</b> 2008; Archer <b>et</b> <b>al.</b> 2009 a; Archer <b>et</b> <b>al.</b> 2009 b; Cheng <b>et</b> <b>al.</b> 2013; Bouchard <b>et</b> <b>al.</b> 2012; Pinkerton <b>et</b> <b>al.</b> 2013), and CREs (Drewe <b>et</b> <b>al.</b> 2013; Lopatka <b>et</b> <b>al.</b> 2007; Vermes <b>et</b> <b>al.</b> 2005; Liske <b>et</b> <b>al.</b> 2002; Frei-Kleiner <b>et</b> <b>al.</b> 2005; Schellenberg <b>et</b> <b>al.</b> 2012; Osmers <b>et</b> <b>al.</b> 2005; Ross 2012; Newton <b>et</b> <b>al.</b> 2006; Geller <b>et</b> <b>al.</b> 2009; Stoll 1987; Wuttke <b>et</b> <b>al.</b> 2003; Nappi <b>et</b> <b>al.</b> 2005; Bai <b>et</b> <b>al.</b> 2007; Uebelhack <b>et</b> <b>al.</b> 2006; Briese <b>et</b> <b>al.</b> 2007; Oktem <b>et</b> <b>al.</b> 2007; Huang <b>et</b> <b>al.</b> 2013; Pockaj <b>et</b> <b>al.</b> 2004; Jacobson <b>et</b> <b>al.</b> 2001; Pockaj <b>et</b> <b>al.</b> 2006; Hernández Munoz & Pluchino 2003; Rostock <b>et</b> <b>al.</b> 2011).|$|R
30|$|The culture {{isolated}} had {{efficiency of}} accumulating on the sheets. Similar biodegradation assay {{has been documented}} by Satlewal <b>et</b> <b>al.</b> Sah <b>et</b> <b>al.,</b> Kapri <b>et</b> <b>al.</b> 2010 a, Kapri <b>et</b> <b>al.</b> 2010 b, Negi <b>et</b> <b>al.,</b> Soni <b>et</b> <b>al.</b> (Negi <b>et</b> <b>al.</b> 2009; Negi <b>et</b> <b>al.</b> 2011; Sah <b>et</b> <b>al.</b> 2010 a; Satlewal <b>et</b> <b>al.</b> 2008; Soni <b>et</b> <b>al.</b> 2009; Soni <b>et</b> <b>al.</b> 2008).|$|R
30|$|Five {{articles}} reported OR (Abnet <b>et</b> <b>al.</b> 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Patel <b>et</b> <b>al.</b> 2013), two reported HR (Abnet <b>et</b> <b>al.</b> 2005 a; Michaud <b>et</b> <b>al.</b> 2008) and {{the other}} one reported RR (Abnet <b>et</b> <b>al.</b> 2001). One article was exclusive to men (Michaud <b>et</b> <b>al.</b> 2008), whereas the remaining studies included both men and women (Abnet <b>et</b> <b>al.</b> 2001, 2005 a, 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Patel <b>et</b> <b>al.</b> 2013). One article did not adjust for confounding factors (Patel <b>et</b> <b>al.</b> 2013), but the other seven articles adjusted to various risk factors for oesophageal cancer, such as age, sex and education (Abnet <b>et</b> <b>al.</b> 2001, 2005 a, 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Michaud <b>et</b> <b>al.</b> 2008). In addition, six articles controlled adjusted values, such as smoking and alcohol drinking (Abnet <b>et</b> <b>al.</b> 2001, 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Michaud <b>et</b> <b>al.</b> 2008).|$|R
30|$|Significant {{progress}} {{has occurred in}} the construction of the chronological framework for the thick, continuous Quaternary loess sediments over throughout northern China (Heller and Liu 1982; Burbank and Li 1985; Liu 1985; Kukla 1987; Kukla <b>et</b> <b>al.</b> 1988; Liu <b>et</b> <b>al.</b> 1988; Rolph <b>et</b> <b>al.</b> 1989; Yue 1989, 1995; An <b>et</b> <b>al.</b> 1991; Zheng <b>et</b> <b>al.</b> 1992; Ding <b>et</b> <b>al.</b> 1994, 2002; Porter and An 1995; Lu <b>et</b> <b>al.</b> 1999; Heslop <b>et</b> <b>al.</b> 2000; Sun <b>et</b> <b>al.</b> 2006; Liu <b>et</b> <b>al.</b> 2015). Additionally, numerous studies have focused on the exact identification and/or detailed processes of geomagnetic reversals (Heller and Liu 1982; Sun <b>et</b> <b>al.</b> 1993; Zhu <b>et</b> <b>al.</b> 1994; Spassov <b>et</b> <b>al.</b> 2001, 2003; Pan <b>et</b> <b>al.</b> 2002; Liu <b>et</b> <b>al.</b> 2008; Yang <b>et</b> <b>al.</b> 2005, 2010, 2014; Jin and Liu 2010, 2011 b; Wang <b>et</b> <b>al.</b> 2014; Zhao <b>et</b> <b>al.</b> 2014; Zhou <b>et</b> <b>al.</b> 2014) and excursions (Zhu <b>et</b> <b>al.</b> 1998, 1999; Fang <b>et</b> <b>al.</b> 1997; Pan <b>et</b> <b>al.</b> 2002; Yang <b>et</b> <b>al.</b> 2004, 2007 a, 2007 b, 2008; Jin <b>et</b> <b>al.</b> 2012; Sun <b>et</b> <b>al.</b> 2013) recorded in Chinese loess.|$|R
30|$|In {{order to}} solve the problem of {{positioning}} and navigation in GNSS-degraded or denied areas, diverse technologies are broadly researched (Kraemer and Eisfeller, 2009). Most research topics focus on high-sensitivity GNSS (Syrjärinne, 2001), optical navigation systems (Mulloni <b>et</b> <b>al.,</b> 2009, Rouzaud and Skaloud, 2011, Zhou <b>et</b> <b>al.,</b> 2015), acoustic solutions (Priyantha <b>et</b> <b>al.,</b> 2000, Jiang <b>et</b> <b>al.,</b> 2015) 0, WiFi (Bahl and Padmanabhan, 2000), Bluetooth (Pei <b>et</b> <b>al.,</b> 2010 a, Pei <b>et</b> <b>al.,</b> 2010 b, Pei et al.,  2010 c, Chen <b>et</b> <b>al.,</b> 2011 a, Chen <b>et</b> <b>al.,</b> 2012 a, Chen <b>et</b> <b>al.,</b> 2013), ZigBee (Sugano <b>et</b> <b>al.,</b> 2006), Ultra Wide Band (Pahlavan <b>et</b> <b>al.,</b> 2006), cellular networks (Syrjärinne, 2001), RFID (Hightower <b>et</b> <b>al.,</b> 2000), magnetic localization (Storms, 2010), inertial measurement units (Foxlin, 2005 and Chen <b>et</b> <b>al.,</b> 2010), signals of opportunity (Mathews <b>et</b> <b>al.,</b> 2011, Chen <b>et</b> <b>al.,</b> 2012 b, Pei <b>et</b> <b>al.,</b> 2016), dead reckoning approaches (Pei <b>et</b> <b>al.,</b> 2011 c, Chen <b>et</b> <b>al.,</b> 2011 c, Pei <b>et</b> <b>al.,</b> 2012 a, Pei <b>et</b> <b>al.,</b> 2013, Qian <b>et</b> <b>al.,</b> 2015 a, Qian <b>et</b> <b>al.,</b> 2015 b), and also hybrid solutions (Chen <b>et</b> <b>al.,</b> 2009, Pei <b>et</b> <b>al.,</b> 2009, Pahlavan <b>et</b> <b>al.,</b> 2010, Liu <b>et</b> <b>al.,</b> 2010, Chen <b>et</b> <b>al.,</b> 2011 b, Kuusniemi <b>et</b> <b>al.,</b> 2012, and Liu 2012 a, Liu <b>et</b> <b>al.,</b> 2012 b).|$|R
30|$|Sequenced rice genome has {{provided}} {{new technologies and}} tools in functional genomics, transcriptomics and proteomics of important agronomic traits in rice. At present, trends in molecular biology are fully updated. Therefore, by availing the different molecular approaches as, whole genome sequencing of 3000 rice accessions (Li <b>et</b> <b>al.</b> 2014), Genome-wide association mapping (Huang <b>et</b> <b>al.</b> 2010; Zhao <b>et</b> <b>al.</b> 2011; Varshney <b>et</b> <b>al.</b> 2014; McCouch <b>et</b> <b>al.</b> 2016; Yano <b>et</b> <b>al.</b> 2016; Wang <b>et</b> <b>al.</b> 2016; Edzesi <b>et</b> <b>al.</b> 2016; Biscarini <b>et</b> <b>al.</b> 2016; Si <b>et</b> <b>al.</b> 2016); Whole Genome SNP Array (Hu <b>et</b> <b>al.</b> 2013; Yu <b>et</b> <b>al.</b> 2014; Singh <b>et</b> <b>al.</b> 2015; Malik <b>et</b> <b>al.</b> 2016), Genomic-based genotyping platforms and re-sequencing (Gao <b>et</b> <b>al.</b> 2013; Han and Huang 2013; Chen <b>et</b> <b>al.</b> 2013; Barabaschi <b>et</b> <b>al.</b> 2016; Guo <b>et</b> <b>al.</b> 2014; Xu and Bai 2015), Genome-guided RNA-seq (Loraine <b>et</b> <b>al.</b> 2013; Szczesniak <b>et</b> <b>al.</b> 2013; Biselli <b>et</b> <b>al.</b> 2015; Peng <b>et</b> <b>al.</b> 2016; Badoni <b>et</b> <b>al.</b> 2016), Map-based cloning approach (Salvi and Tuberosa 2005; Price 2006; Shomura <b>et</b> <b>al.</b> 2008; Zhang <b>et</b> <b>al.</b> 2013), Transcriptome profiling (Mochida and Shinozaki 2010; Chandel <b>et</b> <b>al.</b> 2011; Venu <b>et</b> <b>al.</b> 2011), Genomics approaches (Mochida and Shinozaki 2010; Swamy and Kumar 2013; Varshney <b>et</b> <b>al.</b> 2014; Spindel <b>et</b> <b>al.</b> 2015; Okazaki and Saito 2016) Sequencing-By-Synthesis (SBS) (Venu <b>et</b> <b>al.</b> 2011; Sun <b>et</b> <b>al.</b> 2015), Next generation sequencing (NGS) technologies (Uchida <b>et</b> <b>al.</b> 2011; Miyao <b>et</b> <b>al.</b> 2012; James <b>et</b> <b>al.</b> 2013; Guo <b>et</b> <b>al.</b> 2014; Wang <b>et</b> <b>al.</b> 2016; Matsumoto <b>et</b> <b>al.</b> 2016) and etc. could be strategically exploited to understand molecular mechanism and their relation between the genotypes and phenotypic traits.|$|R
30|$|Regarding {{the number}} of plugs used in each mosaicplasty and their size, both varied across the studies. When {{considering}} {{the number of}} plugs, {{the majority of the}} studies used 3 or less plugs per each mosaicplasty procedure, either for the knee (6 / 11) (Hangody <b>et</b> <b>al.</b> 2010; Espregueira-Mendes <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Clavé <b>et</b> <b>al.</b> 2016) or ankle joints (8 / 10) (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Hangody <b>et</b> <b>al.</b> 2001 a; Kim <b>et</b> <b>al.</b> 2012; Lee <b>et</b> <b>al.</b> 2003; Valderrabano <b>et</b> <b>al.</b> 2009). The remaining studies reported more than 3 plugs used per patient (Gudas <b>et</b> <b>al.</b> 2005; Atik <b>et</b> <b>al.</b> 2005; Gautier <b>et</b> <b>al.</b> 2002; Jakob <b>et</b> <b>al.</b> 2002; Quarch <b>et</b> <b>al.</b> 2014) or did not stated the number of plugs used (Ahmad & Jones 2015; Hangody <b>et</b> <b>al.</b> 2008). Concerning the plugs size, for the knee joint the plugs’ size averages ranged from 2.9 to 9.4  mm (Hangody <b>et</b> <b>al.</b> 2010; Gudas <b>et</b> <b>al.</b> 2005; Atik <b>et</b> <b>al.</b> 2005; Jakob <b>et</b> <b>al.</b> 2002; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Clavé <b>et</b> <b>al.</b> 2016), and for the ankle joint from 3.5 to 9.3  mm (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Kim <b>et</b> <b>al.</b> 2012; Lee <b>et</b> <b>al.</b> 2003). Five studies (Espregueira-Mendes <b>et</b> <b>al.</b> 2012; Ahmad & Jones 2015; Baltzer & Arnold 2005; Hangody <b>et</b> <b>al.</b> 2008; Valderrabano <b>et</b> <b>al.</b> 2009) did not made any report on the plugs size.|$|R
30|$|Carbon- 11 labeled L-methionine (11 C–MET) is a {{promising}} tracer for imaging brain tumors with {{positron emission tomography}} (PET) (Watanabe <b>et</b> <b>al.</b> 2016; Maffione <b>et</b> <b>al.</b> 2009; Glaudemans <b>et</b> <b>al.</b> 2013). Its synthesis has been previously optimized by 11 C–methylation of L-homocysteine in solution or on a C- 18 Sep-Pak cartridge with or without HPLC purification (Pascali <b>et</b> <b>al.</b> 1999; Tang <b>et</b> <b>al.</b> 2004; Lodia <b>et</b> <b>al.</b> 2007; Lodi <b>et</b> <b>al.</b> 2008; Boschi <b>et</b> <b>al.</b> 2009; Cheung <b>et</b> <b>al.</b> 2009; Quincoces <b>et</b> <b>al.</b> 2010; Pascali <b>et</b> <b>al.</b> 2011; Bogni <b>et</b> <b>al.</b> 2003; Nagren <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998; Fukumura <b>et</b> <b>al.</b> 2004). While most groups reported >[*] 97 % radiochemical purity of 11 C–MET {{at the end of}} synthesis (EOS) even without HPLC purification, the stability of 11 C–MET in the final formulation solution has not been well documented in literature (Pascali <b>et</b> <b>al.</b> 1999; Tang <b>et</b> <b>al.</b> 2004; Lodia <b>et</b> <b>al.</b> 2007; Lodi <b>et</b> <b>al.</b> 2008; Boschi <b>et</b> <b>al.</b> 2009; Cheung <b>et</b> <b>al.</b> 2009; Quincoces <b>et</b> <b>al.</b> 2010; Pascali <b>et</b> <b>al.</b> 2011; Bogni <b>et</b> <b>al.</b> 2003; Nagren <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998).|$|R
30|$|In summary, {{results from}} several {{randomised}} controlled trials (RCTs) in post-menopausal women without cancer (Loprinzi <b>et</b> <b>al.</b> 2002 a; Guttuso <b>et</b> <b>al.</b> 2003; Reddy <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 2007; Butt <b>et</b> <b>al.</b> 2008; Saadati <b>et</b> <b>al.</b> 2013; Agarwal <b>et</b> <b>al.</b> 2014; Pinkerton <b>et</b> <b>al.</b> 2014; Loprinzi <b>et</b> <b>al.</b> 2010) and in breast and prostate cancer survivors (Pandya <b>et</b> <b>al.</b> 2004; Pandya <b>et</b> <b>al.</b> 2005; Bordeleau <b>et</b> <b>al.</b> 2010; Loprinzi <b>et</b> <b>al.</b> 2009; Moraska <b>et</b> <b>al.</b> 2010), gabapentin showed no or a slight effect at lower doses (< 900 mg/d GP) or moderate effects at higher doses, ranging from 44 % (Pandya <b>et</b> <b>al.</b> 2005) to 71 % (Loprinzi <b>et</b> <b>al.</b> 2010; Reddy <b>et</b> <b>al.</b> 2006). The study durations were, in general, short (4 – 8 weeks) except in three studies (Guttuso <b>et</b> <b>al.</b> 2003; Reddy <b>et</b> <b>al.</b> 2006; Saadati <b>et</b> <b>al.</b> 2013) that continued for 12 weeks and two studies for 24 weeks (Agarwal <b>et</b> <b>al.</b> 2014; Pinkerton <b>et</b> <b>al.</b> 2014).|$|R
30|$|Literature survey {{reveals that}} {{quantification}} of Solifenacin in human plasma (Macek <b>et</b> <b>al.</b> [2010]; Mistri <b>et</b> <b>al.</b> [2008]), rat plasma (Yanagihara <b>et</b> <b>al.</b> [2007]), pharmaceutical compounds (Krishna <b>et</b> <b>al.</b> [2010]; Desai <b>et</b> <b>al.</b> [2012]; Rami Reddy <b>et</b> <b>al.</b> [2013]; Desai <b>et</b> <b>al.</b> [2011]), and industrial waste streams (Ann-Marie <b>et</b> <b>al.</b> [2011]) were reported. These methods {{were reported by}} using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-MS/MS) (Macek <b>et</b> <b>al.</b> [2010]; Mistri <b>et</b> <b>al.</b> [2008]; Ann-Marie <b>et</b> <b>al.</b> [2011]), high-performance liquid chromatography (HPLC) (Yanagihara <b>et</b> <b>al.</b> [2007]; Krishna <b>et</b> <b>al.</b> [2010]; Desai <b>et</b> <b>al.</b> [2012]; Rami Reddy <b>et</b> <b>al.</b> [2013]), and HPTLC (Desai <b>et</b> <b>al.</b> [2011]). Among all, quantification of Solifenacin by LC-MS/MS in biological matrices (Macek <b>et</b> <b>al.</b> [2010]; Mistri <b>et</b> <b>al.</b> [2008]; Yanagihara <b>et</b> <b>al.</b> [2007]) was proved best results.|$|R
30|$|Our {{hypothesis}} that PTSD would be predicted by {{fear of death}} {{at the time of}} the earthquake (Bergiannaki <b>et</b> <b>al.</b> 2003; Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003; Kiliç and Ulusoy 2003; Basoglu <b>et</b> <b>al.</b> 2004; Kuwabara <b>et</b> <b>al.</b> 2008) was not confirmed. Additionally, our findings do not confirm the negative impact of property damage, object resource loss (Freedy <b>et</b> <b>al.</b> 1994; Sharan <b>et</b> <b>al.</b> 1996; Armenian <b>et</b> <b>al.</b> 2000; C. C. Chen <b>et</b> <b>al.</b> 2001; Bland <b>et</b> <b>al.</b> 2005; Sattler <b>et</b> <b>al.</b> 2006; C. H. Chen <b>et</b> <b>al.</b> 2007; Kuwabara <b>et</b> <b>al.</b> 2008), or displacement (Kiliç <b>et</b> <b>al.</b> 2011; Kiliç <b>et</b> <b>al.</b> 2006; Kiliç and Ulusoy 2003; Najarian <b>et</b> <b>al.</b> 2001; Najarian <b>et</b> <b>al.</b> 1996) in predicting PTSD.|$|R
30|$|Initial {{therapy for}} {{symptomatic}} BPH is medical, typically 5 -alpha-reductase inhibitors or alpha blockers. However, for many patients, {{this is not}} sufficient and intervention is needed. Recently, prostate artery embolization (PAE) has been developed as a minimally invasive means to treat BPH related LUTS. Initial early and midterm results have been very promising (Bilhim <b>et</b> <b>al.</b> 2013 a; Li <b>et</b> <b>al.</b> 2015; Pisco <b>et</b> <b>al.</b> 2013 a; Pisco <b>et</b> <b>al.</b> 2011; Pisco <b>et</b> <b>al.</b> 2012; Pisco <b>et</b> <b>al.</b> 2013 b; Pisco <b>et</b> <b>al.</b> 2016 a; Pisco <b>et</b> <b>al.</b> 2016 b; Antunes <b>et</b> <b>al.</b> 2013; Bagla <b>et</b> <b>al.</b> 2014; Ray <b>et</b> <b>al.</b> 2018; Abt <b>et</b> <b>al.</b> 2018; Grosso <b>et</b> <b>al.</b> 2015; Kurbatov <b>et</b> <b>al.</b> 2014; Wang <b>et</b> <b>al.</b> 2015; Wang <b>et</b> <b>al.</b> 2016; Amouyal <b>et</b> <b>al.</b> 2016 a; Carnevale <b>et</b> <b>al.</b> 2010; Carnevale <b>et</b> <b>al.</b> 2011; Carnevale <b>et</b> <b>al.</b> 2012; De Assis <b>et</b> <b>al.</b> 2015; Gao <b>et</b> <b>al.</b> 2014; Bilhim <b>et</b> <b>al.</b> 2015; Carnevale <b>et</b> <b>al.</b> n.d.; Goncalves <b>et</b> <b>al.</b> 2016; Bilhim <b>et</b> <b>al.</b> 2013 b; Yu <b>et</b> <b>al.</b> 2017; Carnevale <b>et</b> <b>al.</b> 2017; Amouyal <b>et</b> <b>al.</b> 2016 b; Bagla <b>et</b> <b>al.</b> 2013; Carnevale <b>et</b> <b>al.</b> 2014). As further data is being published this exciting technique is slowly moving from the research setting to everyday clinical practice as demonstrated by its mention in the updated National Institute for Health and Care Excellence (NICE) guidelines for LUTS. Here in, the authors review the patient selection process, clinical management of, and expected results for PAE.|$|R
30|$|A {{number of}} studies have {{predicted}} that the first stars and galaxies have distinct observational signatures. One of the most promising signatures stems from Population III SNe (e.g. de Souza <b>et</b> <b>al.</b> 2014). The resulting lightcurves may show the characteristics of core-collapse SNe (Meiksin and Whalen 2013; Whalen <b>et</b> <b>al.</b> 2013 b, 2013 g), pair-instability SNe (Scannapieco <b>et</b> <b>al.</b> 2005; Weinmann and Lilly 2005; Hummel <b>et</b> <b>al.</b> 2012; Pan <b>et</b> <b>al.</b> 2012; de Souza <b>et</b> <b>al.</b> 2013 b; Whalen <b>et</b> <b>al.</b> 2013 a, 2013 f, 2014), gamma-ray bursts (Bromm and Loeb 2002, 2006; Choudhury and Srianand 2002; Islam <b>et</b> <b>al.</b> 2004; Natarajan <b>et</b> <b>al.</b> 2005; Hirose <b>et</b> <b>al.</b> 2006; Belczynski <b>et</b> <b>al.</b> 2007; Inoue <b>et</b> <b>al.</b> 2007; Naoz and Barkana 2007; Salvaterra <b>et</b> <b>al.</b> 2007, 2008; Salvaterra and Chincarini 2007; Komissarov and Barkov 2010; Mészáros and Rees 2010; Campisi <b>et</b> <b>al.</b> 2011; de Souza <b>et</b> <b>al.</b> 2011, 2012; Toma <b>et</b> <b>al.</b> 2011; Nakauchi <b>et</b> <b>al.</b> 2012; Wang <b>et</b> <b>al.</b> 2012; Macpherson <b>et</b> <b>al.</b> 2013; Elliott <b>et</b> <b>al.</b> 2014; Maio and Barkov 2014; Mesler <b>et</b> <b>al.</b> 2014), or even super-massive stars (Whalen <b>et</b> <b>al.</b> 2013 c, 2013 d, 2013 h). More exotic signatures include the neutrino emission accompanying a SN explosion (Fryer <b>et</b> <b>al.</b> 2001; Iocco <b>et</b> <b>al.</b> 2005, 2008 b; Nakazato <b>et</b> <b>al.</b> 2006; Suwa <b>et</b> <b>al.</b> 2009), and gravitational waves from BH binaries (Fryer <b>et</b> <b>al.</b> 2001; Belczynski <b>et</b> <b>al.</b> 2004; Kulczycki <b>et</b> <b>al.</b> 2006; Suwa <b>et</b> <b>al.</b> 2007 a; Kinugawa <b>et</b> <b>al.</b> 2014).|$|R
